Bhawani Jayashree, Shukla Samarth, Acharya Sourya, Vagha Sunita, Jagtap Miheer
Department of Pathology, Jawaharlal Nehru Medical college, Sawangi(Meghe), Wardha, Maharashtra, 442001, India.
Department of General Medicine, Jawaharlal Nehru Medical College, Sawangi(Meghe), Wardha, Maharashtra, 442001, India.
F1000Res. 2024 Jun 18;12:1057. doi: 10.12688/f1000research.138776.2. eCollection 2023.
Breast cancer is the most prevalent cancer among women worldwide and is a well-known cause for cancer mortality in females. COX-2 (cyclooxygenase) plays a vital role in development of some human cancers such as lung, colon and breast. It is a potent enzyme that is important for the conversion of arachidonic acid into prostaglandins. These prostaglandins mediate cellular proliferation, apoptosis and angiogenesis which contributes to carcinogenesis. Overexpression of COX-2 has been detected in several malignancies including breast cancer. COX-2 overexpression is regarded as a poor prognostic marker of breast cancer.The present study will aim to study the immunohistochemical expression of COX-2 in breast cancer and compare it with known histopathological parameters thus assessing its prognostic value.
This will be an observational study conducted in the Department of Pathology, JNMC, Wardha (Sawangi). Radical mastectomy specimens will be studied for COX-2 expression by immunohistochemistry in patients diagnosed with breast carcinoma. COX-2 expression will be quantified as immunohistochemical score and results will be correlated with various histopathological parameters.
The expected result of our study will suggest an association of COX-2 expression to the factors associated with poor prognosis in breast carcinoma. A positive correlation is expected between larger tumor size, positive lymph node status, higher T stage and N stage and lymphovascular invasion.
Conclusions will be drawn from the obtained results of the immunohistochemical study by using COX-2- for detection of overexpression of COX-2 when evaluated with TNM staging, histological grading and molecular types of breast cancer.
乳腺癌是全球女性中最常见的癌症,也是女性癌症死亡的一个众所周知的原因。COX-2(环氧化酶)在一些人类癌症如肺癌、结肠癌和乳腺癌的发展中起着至关重要的作用。它是一种重要的酶,对于将花生四烯酸转化为前列腺素很重要。这些前列腺素介导细胞增殖、凋亡和血管生成,从而促进致癌作用。在包括乳腺癌在内的几种恶性肿瘤中已检测到COX-2的过表达。COX-2过表达被认为是乳腺癌预后不良的标志物。本研究旨在研究COX-2在乳腺癌中的免疫组化表达,并将其与已知的组织病理学参数进行比较,从而评估其预后价值。
这将是一项在沃德哈(萨万吉)JNMC病理科进行的观察性研究。将对诊断为乳腺癌的患者的根治性乳房切除术标本进行COX-2表达的免疫组化研究。COX-2表达将被量化为免疫组化评分,结果将与各种组织病理学参数相关联。
我们研究的预期结果将表明COX-2表达与乳腺癌预后不良相关因素之间存在关联。预计肿瘤大小较大、淋巴结阳性状态、较高的T分期和N分期以及淋巴管浸润之间存在正相关。
将通过使用COX-2进行免疫组化研究的所得结果得出结论,以便在与乳腺癌的TNM分期、组织学分级和分子类型一起评估时检测COX-2的过表达。